Evaluation of the effectiveness of oral Aspirin in reducing complex regional pain syndrome (CRPS)

Evaluation of the effectiveness of oral Aspirin in reducing complex regional pain syndrome (CRPS) in distal radius fractures treated with closed reduction and percutaneous pinning

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180116038391N1

Enrollment

Registered

2018-03-03

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Complex regional pain syndrome. Condition 2: distal radius fracture. Complex regional pain syndrome I (CRPS I) Fracture at wrist and hand level

Interventions

Intervention 1: Intervention group: Aspirin 500mg po daily for 7days. Intervention 2: Control group: placebo capsule daily for 7 daye.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: closed, unilateral, extra-articular distal radius fracture eighteen years and over

Exclusion criteria

Exclusion criteria: history of taking medications that were involved in the treatment of CRPS (such as antidepressants, anticonvulsants, corticosteroids and vitamin C) previous wrist or hand fracture on the same side neurovascular injury fractures with high energy mechanism or multiple trauma-injured patients, multiple fractures at different places contraindication to take aspirin and acetaminophen open fractures articular displacement requiring open reduction

Design outcomes

Primary

Measure	Time frame
Complex regional pain syndrome. Timepoint: 2, 4, 6 and 12 week post operation. Method of measurement: Budapest’s criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNima Hosseinzadeh

Iran University of Medical Sciences

hosseinzade.nima@gmail.com+98 21 6435 2264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026